Efficacy of Clostridium Butyricum in Alleviating Anxiety and Depression in Patients With Functional Dyspepsia

NCT07182890 · tracked via the Priya Life Science China tracker

Sponsor

Xijing Hospital of Digestive Diseases

Phase

Phase 4

Started

2025-09-20

Last updated

2026-01-05

Condition(s) studied

Functional DyspepsiaProbioticsDepressionAnxiety

Investigational drug(s) / intervention(s)

Clostridium butyricumplacebo

Clostridium butyricum: Patients with postprandial distress syndrome (PDS) will receive Mosapride Citrate Tablets 5 mg three times daily, along with Clostridium butyricum 1260 mg twice daily. Patients with epigastric pain syndrome (EPS) will receive Esomeprazole Enteric-Coated Tablets 20 mg once daily, along with Clostridium butyricum 1260 mg twice daily.

placebo: Patients with PDS will receive Mosapride Citrate Tablets 5 mg three times daily, plus a placebo identical in appearance and odor to Clostridium butyricum (with identical dosage and frequency). Patients with EPS will receive Esomeprazole Enteric-Coated Tablets 20 mg once daily, plus a placebo identical in appearance and odor to Clostridium butyricum (with identical dosage and frequency).

Study summary

Objective: This study aims to evaluate the effectiveness of Clostridium butyricum in improving anxiety and depression in patients diagnosed with functional dyspepsia according to the Rome IV criteria.

Methods: This trial plans to enroll 180 patients (90 per group). The study will employ a double-blind design. For patients diagnosed with FD according to the Rome IV criteria, in addition to conventional treatment (treated with Mosapride Citrate Tablets (Guangdong Anno Guocai) for Postmeal Discomfort Syndrome (PDS) and Esomeprazole Enteric Coated Tablets (Shijiazhuang Longze Pharmaceutical Guocai) for Upper Abdominal Pain Syndrome (EPS)), the experimental group was treated with Clostridium butyricum, while the control group received a placebo with the same appearance and odor.

The treatment intervention will last for 4 weeks. The main indicator of this experiment is the improvement of the Hospital Anxiety and Depression Scale (HADS score) after 4 weeks of treatment. The secondary indicators are the improvement rate of the overall treatment effectiveness evaluation questionnaire (OTE questionnaire), the improvement of the global overall symptom score (GOS score), the improvement of the simplified Nipin scale (SF-NDI), and the improvement of the Pittsburgh Sleep Index (PSQI) after 4 weeks of treatment. Upon completion of the trial, the patients' conditions will be re-evaluated, and treatment plans will be adjusted accordingly.

Eligibility

Sex

ALL

Min age

18 Years

Max age

80 Years

Healthy volunteers

Inclusion Criteria: * Patients diagnosed with functional dyspepsia (FD) according to the Rome IV criteria. * Aged 18 to 80 years, regardless of gender. * Hospital Anxiety and Depression Scale (HADS) score between 8 and 14. Exclusion Criteria: * Use of probiotics or antibiotics within one month prior to the trial. * Use of psychoactive medications (including hypnotics, sedatives, anxiolytics, or antidepressants) within one month prior to the trial. * Use of hormones, immunosuppressants, or cytotoxic agents within one month prior to the trial. * Participation in any other clinical trial within one month prior to the study. * Positive test for Helicobacter pylori (Hp) infection. * Long-term use of traditional Chinese herbal medicine. * Pregnancy or lactation. * History of drug abuse. * Comorbidities such as irritable bowel syndrome (IBS), gastroesophageal reflux disease (GERD), functional constipation (FC), or other significant conditions that may interfere with the trial-including severe hepatic, renal, respiratory, or autoimmune disorders; bleeding diatheses; psychiatric diseases; endocrine disorders; etc. * History of major surgery or diagnosis of diabetes mellitus. * Refusal to provide written informed consent.

Primary outcome measure(s)

Hospital Anxiety and Depression Scale (HADS) — 4 weeks
Hospital Anxiety and Depression Scale (HADS) is divided into an anxiety subscale (7 questions) and a depression subscale (7 questions), with each subscale scoring 0-21 points. The higher the score, the more severe the patient's anxiety and depression.

Trial sites (1)

Facility	City	Region	Status
Air Force Medical University	Xi’an	Shanxi	Recruiting

More Xijing Hospital of Digestive Diseases trials in China

Fenofibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cholangitis: a Real World Study Recruiting

Advanced Adenoma Detection With 3D Imaging Device During Colonoscopy Recruiting

Selection and Efficacy-Influencing Factors of First-Line Biologic Agents in Moderate-to-Severe Ulcerative Colitis Recruiting

Upadacitinib Versus Infliximab as Second-Line Treatment for Acute Severe Ulcerative Colitis（UPRISE） Recruiting

The Efficacy of Hyperbaric Oxygen-assisted Treatment for ASUC and Refractory IBD Enrolling by invitation

Other trials for the same condition

Multimodal Identification of Depressive Symptoms in the Elderly Starting soon

Adjunctive Resonance-Based Chinese Five-Element Music Intervention for Depressive Disorders and Anxiety Symptoms in Male Inpatients Enrolling by invitation

Effect of Esketamine on Perioperative Negative Emotions in Patients Undergoing Breast Cancer Surgery Starting soon

Transcranial Direct Current Stimulation for Depression Recruiting

Multifaceted Benefits of Auricular Point Sticking for IVF Patients: Psychological Well-being, Sleep, and Treatment Outcomes Enrolling by invitation

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07182890 on ClinicalTrials.gov ↗ ← All trials in China